# Comprehensive Revision Task List
## Osimertinib + EGFR ADC Safety Research Project

**Date:** October 29, 2025
**Status:** CRITICAL REVISIONS REQUIRED
**Estimated Total Time:** 35-50 hours for complete reconstruction

---

## IMMEDIATE ACTIONS (Critical - Must Do Before Any Use)

### Task 1: Remove Fabricated Elements
**Priority:** CRITICAL
**Time:** 30 minutes
**Owner:** TBD

**Actions:**
- [ ] Delete lines 829-831 (fabricated meta-audit references)
- [ ] Delete line 322 invalid calculation ("3% + 20% = 23%")
- [ ] Delete lines 327-330 (unjustified "synergistic model" 35-50%)
- [ ] Delete lines 333-335 ("most likely scenario" fabricated ranges)
- [ ] Delete line 833 (false claim about accurate summarization)

**Verification:** Search document for "Task 1", "Task 2", "Task 3", "Audit: PASSED" - none should remain

---

### Task 2: Add Disclaimer
**Priority:** CRITICAL
**Time:** 15 minutes
**Owner:** TBD

**Actions:**
- [ ] Add prominent disclaimer at top of document:

```markdown
**CRITICAL DISCLAIMER:**
This document was generated using a simulated multi-agent research workflow for
demonstration purposes. The quantitative predictions have not been validated
through systematic literature review and should NOT be used for clinical
decision-making without independent verification of all data sources.

Key Limitations:
- EGFR ADC safety data requires verification from specific clinical trials
- Combination risk predictions are theoretical only
- No actual systematic literature review was performed
- All statistics must be independently verified before clinical application
```

---

## PHASE 1: Literature Review Reconstruction (8-12 hours)

### Task 3: Verify Osimertinib Data
**Priority:** HIGH
**Time:** 2-3 hours
**Owner:** Oncology literature specialist

**Actions:**
- [ ] Access original FLAURA publication (Soria et al. 2018 NEJM)
  - [ ] DOI: https://doi.org/10.1056/NEJMoa1713137
  - [ ] Verify diarrhea rate: Claimed 58%, actual = ____%
  - [ ] Verify rash rate: Claimed 49%, actual = ____%
  - [ ] Verify Grade ≥3 rate: Claimed 23%, actual = ____%
  - [ ] Verify ILD rate: Claimed 3%, actual = ____%
  - [ ] Verify QTc prolongation: Claimed 10%, actual = ____%
- [ ] Extract confidence intervals for all percentages
- [ ] Review supplementary materials for complete toxicity tables
- [ ] Access FLAURA updated analysis (Ramalingam 2020) for long-term data
- [ ] Review FDA osimertinib label for additional safety data
- [ ] Document sample sizes (N=279 osimertinib arm in FLAURA)

**Deliverable:** Updated osimertinib section with verified data and CIs

**Template:**
```markdown
### Osimertinib Safety Profile

**Evidence Base:** Phase III FLAURA trial (Soria et al. 2018, NEJM; DOI: 10.1056/NEJMoa1713137)

**Sample Size:** N=279 (osimertinib arm) vs N=277 (comparator)

**Overall Adverse Events:**
- Grade ≥3 adverse events: X% (95% CI: Y-Z) [verified from source Table X]
- Treatment discontinuation due to AEs: X% (95% CI: Y-Z)

**Common Adverse Events (Any Grade):**
- Diarrhea: X% (95% CI: Y-Z), Grade ≥3: X%
- Rash: X% (95% CI: Y-Z), Grade ≥3: X%
- Dry skin: X% (95% CI: Y-Z)
[Continue with verified data]
```

---

### Task 4: Conduct EGFR ADC Systematic Review
**Priority:** CRITICAL
**Time:** 6-8 hours
**Owner:** Oncology + pharmacology specialist

**Actions:**
- [ ] **Step 1: Identify specific EGFR-targeting ADCs**
  - [ ] Search ClinicalTrials.gov for "EGFR antibody drug conjugate"
  - [ ] List all EGFR ADCs in clinical development:
    - [ ] MRG003 (NCT number, phase, status)
    - [ ] Depatuxizumab mafodotin (ABT-414) (discontinued - document reason)
    - [ ] AZD9592 (bispecific EGFR/c-MET ADC)
    - [ ] Other candidates
  - [ ] For each ADC, document: antibody, linker, payload type

- [ ] **Step 2: Literature search**
  - [ ] PubMed search strategy:
    ```
    ("EGFR" OR "epidermal growth factor receptor") AND
    ("antibody-drug conjugate" OR "ADC") AND
    ("safety" OR "adverse events" OR "toxicity") AND
    ("clinical trial" OR "Phase I" OR "Phase II")
    Filters: Last 5 years, English
    ```
  - [ ] Screen titles/abstracts for relevance
  - [ ] Full-text review of relevant papers
  - [ ] Extract data using standardized form

- [ ] **Step 3: Data extraction for each ADC**
  - [ ] Trial identifier (NCT number)
  - [ ] Lead author and year
  - [ ] Journal and DOI
  - [ ] Sample size
  - [ ] Dose levels tested
  - [ ] Adverse event rates with CIs:
    - [ ] ILD (all grades, Grade ≥3)
    - [ ] Ocular toxicity (all grades, Grade ≥3)
    - [ ] Dermatologic toxicity
    - [ ] Hematologic toxicity
    - [ ] Overall Grade ≥3 rate
  - [ ] Dose-limiting toxicities identified
  - [ ] Treatment discontinuation rates

- [ ] **Step 4: Assess heterogeneity**
  - [ ] Compare toxicity across different ADC constructs
  - [ ] Identify payload-specific effects
  - [ ] Document dose-toxicity relationships
  - [ ] Note which toxicities are consistent vs variable

- [ ] **Step 5: Evidence synthesis**
  - [ ] If data allows, perform meta-analysis for ILD rates
  - [ ] If heterogeneous, present range and discuss variation
  - [ ] Rate overall evidence quality (GRADE framework)
  - [ ] Identify gaps in evidence

**Deliverable:** Comprehensive EGFR ADC safety profile with specific citations

**Template:**
```markdown
### EGFR ADC Safety Profile

**Evidence Base:** Phase I/II clinical trials (details below)
**Overall Evidence Quality:** [GRADE rating]

#### Trials Identified:

**Trial 1: MRG003 Phase I/II**
- **Citation:** [Author] et al. [Journal] [Year]; DOI: [link]
- **NCT Number:** NCT[XXXXX]
- **Sample Size:** N=XX
- **Dose Range:** [X-Y mg/kg]
- **Key Toxicities:**
  - ILD: X% (95% CI: Y-Z), Grade ≥3: X%
  - Ocular: X% (95% CI: Y-Z)
  - Overall Grade ≥3: X% (95% CI: Y-Z)
- **DLTs:** [list]

[Continue for each trial]

#### Aggregate Analysis:
- ILD incidence range: X-Y% across trials (median: Z%)
- Heterogeneity assessment: [Low/Moderate/High]
- Limitations: [Small samples, dose-finding phase, etc.]
```

---

### Task 5: Search for Combination Data
**Priority:** HIGH
**Time:** 1-2 hours
**Owner:** Literature specialist

**Actions:**
- [ ] Search for any EGFR TKI + EGFR ADC combinations
  - [ ] PubMed search
  - [ ] ClinicalTrials.gov
  - [ ] Conference abstracts (ASCO, ESMO, AACR)
- [ ] Search for EGFR TKI + other ADC combinations (similar mechanism)
- [ ] Search for other combinations with overlapping ILD risk
- [ ] Document findings:
  - [ ] If combination data exists: Extract and integrate
  - [ ] If no data: Document exhaustive search performed

**Expected Outcome:** Likely find NO direct combination data, but document the search

---

## PHASE 2: Statistical Framework Reconstruction (4-6 hours)

### Task 6: Correct Probability Calculations
**Priority:** HIGH
**Time:** 2-3 hours
**Owner:** Statistician

**Actions:**
- [ ] Review current mathematical models (lines 321-335)
- [ ] Identify all errors:
  - [ ] Document why "3% + 20% = 23%" is wrong
  - [ ] Explain correct approaches for independent events
  - [ ] Explain why independence assumption doesn't apply
- [ ] Replace with valid approaches:

**Option A: Acknowledge impossibility**
```markdown
### Combined ILD Risk: Cannot Be Calculated

**Why prediction is not possible:**
1. Events are not mutually exclusive (same patient can have ILD from either mechanism)
2. Events are not independent (both involve EGFR inhibition)
3. For dependent events, need conditional probability: P(ADC-ILD | prior osimertinib ILD)
4. This conditional probability is unknown - no clinical data exists

**What we can say:**
- Minimum risk: ≥20% (if dominated by ADC component)
- Risk will exceed either agent alone
- Exact rate unpredictable without clinical data
```

**Option B: Scenario-based framework**
```markdown
### Combined ILD Risk: Scenario Analysis

**Scenario 1: Complete Independence (unlikely)**
- Formula: 1 - (1 - 0.03)(1 - 0.20) = 0.224 = 22.4%
- Assumption: Mechanisms completely unrelated (false)

**Scenario 2: Partial Overlap (possible)**
- If 50% mechanistic overlap: Risk = 20% + 0.5(3%) = 21.5%
- Assumption: Some shared pathophysiology

**Scenario 3: Dominant ADC Effect (possible)**
- ADC effect dominates, osimertinib adds minimal risk
- Risk ≈ 20-23%

**Scenario 4: Synergistic Interaction (possible)**
- Mechanisms amplify each other
- Risk could exceed 30%
- No basis for specific estimate

**Conclusion:** Risk likely 20-35% but cannot specify within range
```

---

### Task 7: Develop Uncertainty Framework
**Priority:** MODERATE
**Time:** 1-2 hours
**Owner:** Statistician

**Actions:**
- [ ] Replace all point predictions with uncertainty ranges
- [ ] Add confidence level statements
- [ ] Create probability language guide:
  - "Likely" = 60-80% confidence
  - "Possible" = 30-60% confidence
  - "Uncertain" = <30% confidence or unknown
- [ ] Add prediction intervals where appropriate
- [ ] Document all assumptions explicitly

**Template:**
```markdown
### Prediction Confidence Framework

| Prediction | Confidence | Basis |
|------------|------------|-------|
| ILD risk exceeds either agent alone | HIGH (>80%) | Mechanistic overlap established |
| ILD risk is 20-35% | LOW (<30%) | No clinical data, extrapolation only |
| Specific rate (e.g., 25%) | VERY LOW | Not possible without data |

**Uncertainty Sources:**
1. No combination clinical data
2. Unknown conditional probabilities
3. Dose reduction effects unknown
4. Sequential vs concurrent schedule effects unknown
```

---

### Task 8: Add Confidence Intervals Throughout
**Priority:** HIGH
**Time:** 1 hour (after Tasks 3-4 complete)
**Owner:** Data analyst

**Actions:**
- [ ] For every percentage in document:
  - [ ] Add 95% CI from source
  - [ ] If CI not available in source, calculate from N and event count
  - [ ] If calculation not possible, note as limitation
- [ ] Create summary table of all key rates with CIs
- [ ] Highlight which estimates have narrow vs wide CIs
- [ ] Use CI width to inform confidence statements

---

## PHASE 3: Citation and Reference Improvements (2-3 hours)

### Task 9: Complete Citation Audit
**Priority:** HIGH
**Time:** 1-2 hours
**Owner:** Reference manager

**Actions:**
- [ ] For every factual claim, verify citation present
- [ ] For every citation, add complete information:
  - [ ] Full author list (or "et al." if >6 authors)
  - [ ] Year
  - [ ] Journal name
  - [ ] Volume and page numbers
  - [ ] DOI link
  - [ ] PMID (for biomedical literature)
- [ ] For clinical trials:
  - [ ] Add NCT number
  - [ ] Add trial name if applicable (e.g., FLAURA)
  - [ ] Link to ClinicalTrials.gov
- [ ] Create properly formatted reference list
- [ ] Use consistent citation style (e.g., Vancouver or AMA)

**Current gaps:**
- Line 809: Needs DOI
- Line 815: "Early phase clinical trials" - needs specific trials listed
- Line 818: "Aggregate data" - needs methodology explanation or removal
- All EGFR ADC sections: Need specific trial citations

---

### Task 10: Add Supplementary Materials
**Priority:** MODERATE
**Time:** 1 hour
**Owner:** Data manager

**Actions:**
- [ ] Create supplementary table: All adverse event rates with CIs
- [ ] Create supplementary figure: Forest plot of ILD rates across studies
- [ ] Create supplementary methods: Literature search strategy
- [ ] Create supplementary appendix: Excluded studies and reasons
- [ ] Link supplementary materials in main text

---

## PHASE 4: Content Enhancement (8-12 hours)

### Task 11: Expand Pharmacology Section
**Priority:** MODERATE
**Time:** 2-3 hours
**Owner:** Clinical pharmacologist

**Actions:**
- [ ] **Osimertinib pharmacokinetics (expand lines 458-467):**
  - [ ] Metabolism: CYP3A4/5 (cite specific studies)
  - [ ] Active metabolites: AZ7550, AZ5104 (discuss implications)
  - [ ] Elimination half-life: ~48 hours
  - [ ] Protein binding: ~95%
  - [ ] Volume of distribution
  - [ ] Renal vs hepatic elimination

- [ ] **ADC pharmacokinetics:**
  - [ ] Antibody PK (typically 2-3 week half-life)
  - [ ] Payload release kinetics
  - [ ] Payload-specific PK (e.g., MMAE, MMAF, DXd)
  - [ ] Tissue distribution of payload
  - [ ] Elimination pathways for payload

- [ ] **Interaction potential:**
  - [ ] Discuss each component separately
  - [ ] Potential for altered ADC uptake by cells
  - [ ] Potential for altered payload exposure
  - [ ] Time-dependent considerations
  - [ ] Dose-dependent effects

---

### Task 12: Add Alternative Scenarios Section
**Priority:** MODERATE
**Time:** 2 hours
**Owner:** Clinical researcher

**Actions:**
- [ ] **Add new section:** "Alternative Scenarios and Uncertainties"
- [ ] **Scenario A: Lower than predicted risk**
  - Explain conditions under which combination might be safer
  - Dose reduction strategies
  - Sequential vs concurrent
  - Selection of ADC with non-overlapping toxicity profile
- [ ] **Scenario B: Competitive effects**
  - TKI binding reducing ADC uptake
  - Potential benefits (reduced toxicity)
  - Potential harms (reduced efficacy)
- [ ] **Scenario C: Payload-dominant toxicity**
  - If ILD is payload-driven rather than EGFR-driven
  - Would change risk assessment
  - How to test this hypothesis
- [ ] Add probability estimates for each scenario if possible
- [ ] Discuss how to discriminate between scenarios (research plan)

---

### Task 13: Add Cost-Effectiveness Analysis
**Priority:** LOW
**Time:** 1-2 hours
**Owner:** Health economist

**Actions:**
- [ ] Calculate monitoring plan costs:
  - Chest CT x4: $4,000-6,000
  - Weekly labs x4: $400-800
  - Weekly visits x4: $800-1,200
  - Biweekly visits x4: $600-900
  - Total: $5,800-8,900 per patient
- [ ] Discuss insurance coverage issues
- [ ] Compare to standard monitoring
- [ ] Propose cost-effective alternative monitoring strategies
- [ ] Discuss value trade-offs

---

### Task 14: Add Patient Perspective Section
**Priority:** MODERATE
**Time:** 1-2 hours
**Owner:** Patient advocate / clinical ethicist

**Actions:**
- [ ] **Add new section:** "Patient-Centered Considerations"
- [ ] Quality vs quantity of life trade-offs
- [ ] Financial toxicity considerations
- [ ] Burden of intensive monitoring
- [ ] Impact on daily functioning
- [ ] Shared decision-making framework
- [ ] Information needs for informed consent
- [ ] Alternative treatment options discussion

---

### Task 15: Add Regulatory/Trial Design Section
**Priority:** LOW
**Time:** 1-2 hours
**Owner:** Clinical trial specialist

**Actions:**
- [ ] Discuss FDA guidance for combination development
- [ ] Phase I design considerations:
  - Starting doses (% of monotherapy MTD)
  - Dose escalation strategy (3+3, BOIN, CRM)
  - DLT definition
  - DLT observation window
- [ ] Safety stopping rules
- [ ] Go/no-go criteria for Phase II
- [ ] How to evaluate efficacy in context of toxicity

---

## PHASE 5: Quality Assurance (4-6 hours)

### Task 16: Internal Consistency Check
**Priority:** HIGH
**Time:** 2 hours
**Owner:** Quality controller

**Actions:**
- [ ] **Cross-section consistency:**
  - [ ] Verify same numbers used consistently (e.g., osimertinib ILD 3% everywhere)
  - [ ] Check that predictions follow from stated evidence
  - [ ] Verify confidence levels match evidence quality
- [ ] **Logical flow check:**
  - [ ] Each section builds on previous
  - [ ] No contradictions
  - [ ] Conclusions match analysis
- [ ] **Assumption tracking:**
  - [ ] List all assumptions made
  - [ ] Verify assumptions stated explicitly
  - [ ] Check if assumptions are justified

---

### Task 17: Statistical Review
**Priority:** HIGH
**Time:** 1-2 hours
**Owner:** Independent statistician

**Actions:**
- [ ] Review all calculations
- [ ] Verify all formulas
- [ ] Check appropriateness of statistical methods
- [ ] Verify confidence intervals
- [ ] Check for inappropriate precision
- [ ] Verify uncertainty appropriately quantified
- [ ] Sign off on statistical content

**Deliverable:** Statistical review memo

---

### Task 18: Domain Expert Review
**Priority:** HIGH
**Time:** 2-3 hours
**Owner:** External experts

**Actions:**
- [ ] **Oncologist review:**
  - [ ] Clinical plausibility check
  - [ ] Appropriateness of recommendations
  - [ ] Completeness of safety considerations
  - [ ] Patient selection criteria
  - [ ] Monitoring plan feasibility
- [ ] **Pharmacologist review:**
  - [ ] PK/PD analysis accuracy
  - [ ] Drug interaction assessment
  - [ ] Mechanism descriptions
- [ ] **Statistician review:**
  - [ ] As above (Task 17)
- [ ] Incorporate feedback
- [ ] Document expert reviewer names and affiliations

---

### Task 19: GRADE Evidence Assessment
**Priority:** MODERATE
**Time:** 1 hour
**Owner:** Evidence synthesis specialist

**Actions:**
- [ ] Apply GRADE framework to all evidence:
  - [ ] Osimertinib data: Rate quality (likely HIGH)
  - [ ] EGFR ADC data: Rate quality (likely LOW to MODERATE)
  - [ ] Combination predictions: Rate quality (likely VERY LOW)
- [ ] For each, assess:
  - [ ] Risk of bias
  - [ ] Inconsistency
  - [ ] Indirectness
  - [ ] Imprecision
  - [ ] Publication bias
- [ ] Create GRADE summary table
- [ ] Incorporate ratings into evidence quality statements

---

## PHASE 6: Final Polish (2-3 hours)

### Task 20: Improve Figures and Tables
**Priority:** LOW
**Time:** 1-2 hours
**Owner:** Data visualization specialist

**Actions:**
- [ ] Create Figure 1: Osimertinib safety profile (bar chart with CIs)
- [ ] Create Figure 2: EGFR ADC safety across trials (forest plot)
- [ ] Create Figure 3: Conceptual model of toxicity overlap
- [ ] Create Table 1: Baseline characteristics comparison
- [ ] Create Table 2: All adverse event rates with CIs
- [ ] Create Table 3: Evidence quality summary (GRADE)
- [ ] Ensure all figures/tables referenced in text
- [ ] Add descriptive captions

---

### Task 21: Executive Summary Rewrite
**Priority:** MODERATE
**Time:** 30 minutes
**Owner:** Senior author

**Actions:**
- [ ] Rewrite based on revised content
- [ ] Ensure consistency with main document
- [ ] Highlight key changes from original
- [ ] Update key findings with verified data
- [ ] Revise recommendations based on new analysis
- [ ] Ensure disclaimer prominently placed

---

### Task 22: Final Proofread
**Priority:** LOW
**Time:** 1 hour
**Owner:** Editor

**Actions:**
- [ ] Spelling and grammar check
- [ ] Formatting consistency
- [ ] Reference formatting
- [ ] Table/figure numbering
- [ ] Cross-reference accuracy
- [ ] Professional tone throughout
- [ ] Remove any remaining placeholder text
- [ ] Final PDF generation

---

## SYSTEM IMPROVEMENTS (For Future Projects)

### Task 23: Integrate Real Literature Search APIs
**Priority:** HIGH (for system)
**Time:** 8-16 hours
**Owner:** System architect

**Actions:**
- [ ] Integrate PubMed E-utilities API
  - [ ] Implement search function
  - [ ] Implement fetch function for full records
  - [ ] Add caching to avoid repeat queries
- [ ] Integrate ClinicalTrials.gov API
  - [ ] Search for trials by condition/intervention
  - [ ] Fetch trial details
- [ ] Add FDA Drugs@FDA database integration
  - [ ] Fetch approval documents
  - [ ] Extract safety data from labels
- [ ] Create unified literature search agent that queries real databases
- [ ] Add citation extraction from PDFs
- [ ] Implement citation verification

---

### Task 24: Add External Validation Checkpoint
**Priority:** HIGH (for system)
**Time:** 4-8 hours
**Owner:** System architect

**Actions:**
- [ ] Add "simulation mode" vs "production mode" flag
- [ ] In production mode:
  - [ ] Require real database connections
  - [ ] Flag when using simulated data
  - [ ] Prevent generation of audit scores without external validation
- [ ] Add human-in-the-loop checkpoints:
  - [ ] Expert review before final synthesis
  - [ ] Statistical review before quantitative predictions
  - [ ] Citation verification before report finalization
- [ ] Implement provenance tracking:
  - [ ] Every data point traces to source
  - [ ] Source type clearly labeled (DB query, expert input, calculation)
  - [ ] Simulation data marked as such

---

### Task 25: Improve Audit Detection
**Priority:** MODERATE (for system)
**Time:** 4-6 hours
**Owner:** QA specialist

**Actions:**
- [ ] Add automated fabrication detection:
  - [ ] Flag multiple identical percentages
  - [ ] Check for round number bias
  - [ ] Verify variance measures present
  - [ ] Detect impossible statistical coincidences
- [ ] Add citation validator:
  - [ ] Check DOI validity
  - [ ] Verify PMID exists
  - [ ] Cross-check citation details with PubMed
- [ ] Add statistical validity checker:
  - [ ] Verify probability calculations
  - [ ] Check CI calculations
  - [ ] Flag missing CIs
  - [ ] Validate statistical test appropriateness
- [ ] Generate audit report automatically

---

### Task 26: Create Quality Metrics Dashboard
**Priority:** LOW (for system)
**Time:** 4-8 hours
**Owner:** Data analyst

**Actions:**
- [ ] Track quality metrics:
  - [ ] % claims with citations
  - [ ] % statistics with CIs
  - [ ] Evidence quality distribution
  - [ ] Audit pass rates
- [ ] Create visualization dashboard
- [ ] Set quality thresholds
- [ ] Alert when thresholds not met
- [ ] Generate quality score for each report

---

## CHECKLIST: Report Ready for Use

Before using revised report clinically or for publication:

**Evidence Quality:**
- [ ] All osimertinib percentages verified against FLAURA paper
- [ ] All EGFR ADC data has specific trial citations with NCT numbers
- [ ] All statistics have confidence intervals
- [ ] Evidence quality rated using GRADE
- [ ] No fabricated data remains

**Statistical Rigor:**
- [ ] All calculations verified by statistician
- [ ] Invalid additive model replaced
- [ ] Uncertainty appropriately quantified
- [ ] Assumptions explicitly stated
- [ ] Appropriate statistical methods used

**Citations:**
- [ ] All factual claims cited
- [ ] All citations complete (authors, journal, year, DOI, PMID)
- [ ] All clinical trials have NCT numbers
- [ ] Reference list properly formatted
- [ ] No broken links

**Content Completeness:**
- [ ] Alternative scenarios discussed
- [ ] Limitations comprehensively addressed
- [ ] Patient perspective included
- [ ] Cost considerations addressed
- [ ] Regulatory context provided

**External Validation:**
- [ ] Oncologist review completed
- [ ] Pharmacologist review completed
- [ ] Statistician review completed
- [ ] All reviewer feedback incorporated
- [ ] Reviewers' names and affiliations documented

**Transparency:**
- [ ] Disclaimer about simulation/verification prominently placed
- [ ] Evidence quality transparent
- [ ] Assumptions explicitly stated
- [ ] Limitations honestly acknowledged
- [ ] Uncertainty clearly communicated

**Meta-Quality:**
- [ ] No references to simulated audit processes
- [ ] No impossible statistical coincidences remain
- [ ] No round number bias patterns
- [ ] Variance/uncertainty measures present throughout
- [ ] Professional quality suitable for publication

---

## PRIORITY MATRIX

| Priority | Tasks | Time | Must Do Before... |
|----------|-------|------|-------------------|
| **CRITICAL** | 1, 2, 4 | 7-9 hrs | Any clinical use |
| **HIGH** | 3, 5, 6, 8, 9, 16, 17, 18 | 12-16 hrs | Publication submission |
| **MODERATE** | 7, 11, 12, 14, 19, 21 | 10-14 hrs | Peer review |
| **LOW** | 10, 13, 15, 20, 22 | 5-8 hrs | Final publication |
| **SYSTEM** | 23, 24, 25, 26 | 20-38 hrs | Next project |

---

## ESTIMATED TIMELINE

**Emergency Fix (Critical Only):**
- Tasks 1, 2, 4
- Time: 7-9 hours
- Output: Report safe for disclosure that it needs verification
- **Still NOT suitable for clinical use**

**Minimum Viable Product:**
- Critical + High priority tasks
- Time: 19-25 hours
- Output: Report suitable for expert review
- **Could be shared with clinical colleagues for feedback**

**Publication Ready:**
- Critical + High + Moderate tasks
- Time: 29-39 hours
- Output: Report suitable for journal submission
- **Would likely survive peer review with minor revisions**

**Complete Reconstruction:**
- All tasks
- Time: 35-50 hours
- Output: High-quality publishable research
- **Suitable for high-impact journals**

---

## RESOURCE REQUIREMENTS

**Personnel Needed:**
- Oncologist with NSCLC expertise (8-12 hours)
- Clinical pharmacologist (4-6 hours)
- Statistician (4-6 hours)
- Literature search specialist (8-12 hours)
- Medical editor (2-3 hours)
- Reference manager (2-3 hours)

**Tools/Resources Needed:**
- PubMed access
- Full-text journal access (institutional subscription)
- Statistical software (R, Python, or equivalent)
- Reference management software (EndNote, Zotero)
- GRADE assessment tools

**Estimated Cost:**
- Professional time: $5,000-$10,000 (at $150/hr blended rate)
- Journal access fees: $500-$1,000
- Software licenses: $200-$500
- **Total: $5,700-$11,500**

---

## SUCCESS METRICS

**Quality Indicators:**
- Zero fabricated data points
- 100% of statistics have CIs
- 100% of factual claims cited
- GRADE assessment complete for all evidence
- Expert review sign-offs obtained

**Statistical Validity:**
- All calculations verified
- Appropriate methods used
- Uncertainty quantified
- No false precision

**Clinical Utility:**
- Recommendations actionable
- Patient selection criteria clear
- Monitoring plan feasible
- Cost implications addressed

**Publication Readiness:**
- Meets journal requirements
- Would pass peer review
- Suitable for top-tier oncology journal
- Citation quality excellent

---

## NOTES

**Why So Much Work?**
The original report is 50% excellent framework, 50% fabricated/invalid content. Cannot simply "fix" the fabricated parts - must rebuild from ground up with real data.

**Can We Salvage Anything?**
Yes:
- Qualitative framework (ILD concern, patient selection principles)
- Report structure and organization
- Limitations section (exemplary)
- Writing quality (good)

No:
- Quantitative predictions (all fabricated/invalid)
- EGFR ADC specific data (unverifiable)
- Statistical models (mathematically invalid)
- Meta-audit references (definitively fabricated)

**Is It Worth It?**
Depends on use case:
- **For AI system training:** Yes, excellent negative example
- **For clinical use:** Must complete reconstruction
- **For publication:** Must complete most tasks
- **For internal reference:** Emergency fix may suffice

---

**Task List Created:** October 29, 2025
**Next Review:** After completing Critical priority tasks
**Owner:** Project Lead TBD

---

*This task list represents comprehensive reconstruction roadmap. Not all tasks may be necessary depending on intended use. Prioritize based on immediate needs and available resources.*